Status: Available
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
Trial details
Biological sex: AllType: Expanded AccessSponsor: Kedrion S.p.A.Updated: Oct 5, 2023
Eligibility criteria
Subjects diagnosed with LC associated with Type I plasminogen deficiency, confir... [+3]
Subjects with any condition which, in the opinion of the treating physician or s... [+2]